Pulmonx strives to improve the lives of patients suffering from emphysema with its minimally-invasive, personalized technologies for interventional pulmonology.
The company's commercially available portfolio includes the Zephyr Endobronchial Valve, the most-studied device for endoscopic lung volume reduction; the Chartis System, an assessment tool that identifies collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based quantitative computed tomography (CT) analysis service. In limited release is AeriSeal, a foam-based lung sealant that is expected to significantly expand the treatable patient population for the company's therapies.
This combination the assessment tools and therapeutics enables physicians to successfully predict outcomes and provide optimal treatment for each individual patient.
Used together, these technologies have been proven to improve pulmonary function, exercise capacity and quality of life in emphysema patients across multiple randomized controlled trials and in 12,000 patients worldwide. In fact, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) now includes endobronchial valves in its management recommendations for chronic obstructive pulmonary disease (COPD)1.
The company is invested in building further clinical evidence across patient phenotypes to support the use of its technologies.
Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide. They are currently considered investigational in the United States. The Zephyr® Endobronchial Valve is an investigational device in the US, limited by US law to investigational use. StratX™ and AeriSeal® System are not available in the US.
2017 Landmark data from 2 Multicenter RCTs presented showing substantial clinical benefits for both heterogeneous and homogeneous emphysema patients without collateral ventilation.